ever, only a few are sufficiently common to be of concern. The immunological risks of transfusion have long been recognized. Since the early days of transfusion therapy, acute hemolytic transfusion reactions caused by ABO incompatibility have been dreaded because of their high mortality. Now concern about disease transmission through blood transfusion is in everyone's consciousness. Few things equal the tragedy of patients recovering from their primary illness only to contract a more severe illness brought about by the treatment, as has been seen with the spread of the human immunodeficiency virus type I in the national blood supply before the introduction of testing and improved blood donor screening procedures.
Because there is a growing consensus of the importance of informing patients of the potential adverse effects of transfusion, the article by Capon and Sacher [1] in this issue of the Journal is timely in its thorough review of both acute and delayed hemolytic transfusion reactions. Acute hemolytic transfusion reactions most frequently occur because of the failure to follow correctly several simple procedures. These potentially fatal reactions are not commonly caused by technical errors but by misidentification of patients when samples are drawn for pretransfusion testing or at the time of transfusion.
In contrast, delayed hemolytic transfusion reactions typically occur after an anamnestic immune response in patients previously immunized to red cell antigens other than ABO through previous transfusion or pregnancy. Although pretransfusion testing may be accurately performed, these reactions may still occur if the antibody is not being produced. Delayed hemolytic transfusion reactions often go unrecognized clinically. Although morbidity occurs rarely, patients may be placed at added risk because they may require extra transfusions.
The phenomenal advancement and growth in the the surgical sciences, transplantation, and oncology have occurred in part because of the availability of an adeauate and safe blood supplv. The testing re-quirements and donor screening procedures performed on each unit of blood assure that the safest blood possible is being given to patients. However, the safety of transfusion is directly related to the extent to which all personnel involved in testing blood, ordering transfusions, and administering blood follow a few fundamental procedures: They must accurately perform testing and associated clerical tasks and transfuse blood only when necessary.
The safest transfusion is one planned but never used. Physicians need to reexamine the indications for transfusion. Common practice has been guided by the dogma that a hemoglobin concentration less than 10 gm/dl indicates the need for transfusion. However, it has long been recognized that many patients with severe anemia or patients who refuse transfusions because of religious beliefs do not always need transfusions at this level. The decision to transfuse the blood of a specific patient should rest on sound clinical decision-making rather than on a formula. The need for red cell transfusions can be justified only after careful consideration of the duration of anemia; the volume of extravascular blood loss; and the presence of coexisting illnesses such as pulmonary disease, ischemic heart disease, or cerebrovascular or peripheral vascular disease [2] .
If transfusions are deemed necessary, autologous blood donations, pharmacological agents, recombinant erythropoietin, and synthetic blood substitutes may have a role in reducing the number of homologous red cell transfusions. All of these approaches except for synthetic blood substitutes promise to have a substantial impact on clinical practice.
Autologous blood transfusions eliminate the risk of disease transmission and immunological transfusion reactions. Most elective surgical patients who do not have illnesses that strongly contraindicate repeated phlebotomies of 450 ml of blood and who meet the hematocrit requirement of 33% should be encouraged to donate blood in a predeposit blood donation program. Because blood may be stored in the liquid state for 42 days, many patients can easily give 3 to 4 units. of blood over the few weeks before a scheduled surgical procedure.
For patients having elective surgery that will re-quire large amounts of blood for transfusion, the findings from early clinical trials suggest that administration of recombinant erythropoietin may enable some patients to donate several more units of blood than would ordinarily be possible [3] . Because the erythropoietin response is not heightened in the range of red cell mass reduction that occurs with autologous blood donation, administration of recombinant erythropoietin makes sense physiologically [4] . Recombinant A growing list of agents have been used in actively bleeding patients or in those who are likely to bleed after a surgical procedure. These agents have been directed at patients with hemostatic disorders.
The most common pharmacological approach uses 1-desamino-8-D-arginine (DDAVP), which induces the release of large von Willebrand factor multimers from endothelial cells into the circulation, resulting in an increase in Factor VIII:C and von Willebrand activities. DDAVP has been used to treat bleeding in patients with uremia and to reduce surgical bleeding occurring after cardiac surgery [5, 6] . The latter use may substantially reduce the amount of blood administered to cardiac surgical patients. DDAVP is not without risks; myocardial infarctions and stroke have been reported. Another promising pharmacological approach is the use of aprotinin, a serine protease inhibitor that may prevent the platelet defect that is often detected in patients undergoing cardiac surgical procedures. In a trial of 22 patients, 11 receiving aprotinin had a mean blood loss of 286 ml vs 1,509 ml in controls [7] . The greatest changes in transfusion therapy are likely to result from recombinant DNA techniques. Currently, recombinant erythropoietin is being studied extensively in a variety of anemic conditions. It is not unreasonable to speculate that most clinically important plasma factors will be available through the application of recombinant technology. Recombinant factors for treating a variety of conditions requiring blood or blood products will revolutionize the practice of transfusion therapy.
In clinical trials, Eschbach and co-workers [8] showed that, in the anemia of end-stage renal fail-ure, the administration of recombinant erythropoietin can eliminate the need for transfusion. It has shown continuous efficacy in patients who have been treated for several months, and there has been no development of tolerance or antibodies to it. Other applications of recombinant erythropoietin may be for correcting the anemia of chronic disease, post-bone marrow transplantation, perioperative anemia, and in the anemia found in the acquired immunodeficiency syndrome or in malignancies. The cost for each treatment will probably be relatively expensive; however, the cost will need to be measured against reduced transfusion morbidity, reduction of demands on the national blood supply, and improved quality of life for patients. Not all patients can benefit from the measures that avoid homologous transfusion, and these patients should not perceive that homologous transfusions are unsafe. Through the efforts of the blood bank community, scientists, and regulatory agencies and industry, blood transfusions have never been safer, but as with any potent therapy, there are always side effects. Although the medical profession continues to pursue zero-risk forms of therapy, this quest is rarely attainable, even with the vast resources being expended. Thomas 
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